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NUMEROUS studies have revealed that the concentrations of the carbohydrate-
containing proteins in serum are increased above their normal levels in patients
suffering from cancer and also in animals bearing experimental tumours (WVinzler,
1953; Greenspan, 1954; Lockey, Anderson and Maclagan, 1956; Almquist
and Lausing, 1957). Although the observed changes are not considered to be
specificfor cancer since similar variations have been detected in avarietyofclinical
and experimentally induced pathological conditions (Weimer and Moshin, 1952;
Greenspan, 1954; Winzler, 1955; Stary, 1957) considerable interest still exists
regarding the origin and function of serum glycoproteins and factors responsible
for their alteration in disease.
Apparentlyincompatible hypotheseshavebeenproposed toexplaintheincrease
of serum glycoprotein which occurs during tumour growth. From studies of the
serum protein and glycoprotein changes occurring in chronic inflammatory and
malignant disease in man (Seibert, Seibert, Atno and Campbell, 1947) and during
growth of transplanted tumour in mice (Catchpole, 1950), it was concluded that
increases of serum glycoproteins occurred as a result of tissue degeneration. In
contrast, Shetlar, Erwin and Everett (1950) have proposed a completely opposite
hypothesis, namely that serum glycoproteins are produced during processes
involving tissue proliferation, in order to explain their findings on the serum
glycoprotein changes occurring during early stages of growth of the Walker
carcinoma in the rat. A considerable amount of evidence has been reported
in support of both hypotheses whilst studies of the serum glycoprotein changes
during experimentally induced lesions which result in tissue proliferation so far
have failed to resolve the problem (Shetlar, Bryan, Foster, Shetlar and Everett,
1949; Heppleston and Keyser, 1957).
The present investigation was undertaken in order to determine the serum
protein and glycoprotein changes occurring during growth of transplanted and
carcinogen-induced tumours in the rat. Changes in total serum protein concentra-
tion and composition, total serum glycoprotein (protein-bound carbohydrate)
and serum mucoprotein (protein and carbohydrate) have been determined at
various stages oftumour growth. Thus it has been possible to relate serum glyco-
protein increases to the growth activity of the tumour and also to correlate the
changes occurring in the various carbohydrate-containing protein fractions. A
preliminary report of these findings has already been published (British Empire
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MATERIALS AND METHODS
Transplanted tumour studies
The tumour used in these experiments was a transplanted sarcoma (S66)
originally inducedwith methylcholanthrene in inbred Wistar rats (Baldwin, 1955).
This tumour, which was used between the 19th and 36th generation of transfer,
grew readily in all implanted rats and no regressions have ever been recorded.
Inbred Wistar rats (60 to 90 days old) of both sexes were implanted subcu-
taneously in the right dorsal region with standard amounts of tumour taken from
a single donor. At intervals after tumour implantation, groups of 4 to 6 rats
were sacrificed by exsanguination from the heart under ether anaesthesia. Total
body weight was determined and then tumours were excised and weighed. From
these data, tumour growth was assessed as tumour weight and as
tumour weight
residual body weight
(Total body weight - tumour weight).
Carcinogen-induced tumour studies
InbredWistarrats ofboth sexes (60to 80daysold) wereinjectedsubcutaneously
in the right axillary region with a single injection ofmethylcholanthrene (3 mg./0.5
ml.) in olive oil. Animals were examined twice weekly and tumour size was
assessed as the product of the three dimensions of the tumour which were deter-
mined with the aid of callipers. Sera were examined from three groups of rats in
which the induced tumours corresponded approximately in size with 7-, 14- and
21-day-old implants of the transplanted tumour.
Chemical determinations
All chemical analyses were performed in duplicate using a 1/20 dilution of
serum in 0-15 m. NaCl solution.
Total serum protein was determined using the biuret method of Weichselbaum
(1946).
Total serum glycoprotein (Serum protein-bound carbohydrate).-Serum protein
was precipitated with ethanol as described by Weimer and Moshin (1952), and
the carbohydrate content of the precipitated protein was determined by the
tryptophane procedure (Shetlar, Foster and Everett, 1948) using a standard
containing an equimolar mixture ofgalactose and mannose.
Serum mucoprotein was isolated using the procedure of Weimer and Moshin
(1952) and analysed for carbohydrate and protein.
Carbohydrate was determined using the tryptophane procedure.
Protein was estimated using the Folin-Ciocalteau phenol reagent (Kabat and
Mayer, 1948). Although the results are expressed in terms of tyrosine content,
it should be stressed that the Folin reagent is not specific for tyrosine groups in
protein.
Electrophoretic technique
Zone electrophoresis was carried out in an apparatus which was a modification
ofthat described by Franglen, Martin and Treharne (1955); i.e. with a horizontal
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freelysuspendedpaperinamoist chamber. Electrophoreticseparationofundiluted
serum (40pl.) on Whatman No. 3MM. paper was carried out for 24 hours under a
potential gradient of 4 0 volts/cm. in barbitone buffer (pH 8*6; I, 041). Proteins
were located on the paper by staining with bromphenol blue (Hardwicke, 1954)
and protein distribution curves were obtained from analyses of eluted, protein-
bound dye. Protein distribution curves were resolved into components by the
method of Pedersen (1940) and the relative composition was determined from area
measurements.
RESULTS
Transplanted tumour
Theseresults were obtainedfrom three separate experiments in which sera were
analysed at intervals during growth of subcutaneous implants of sarcoma S66 at
the 21st, 23rd and 36th generation of transfer. Although the data have been
combined, it must be emphasised that the serum changes observed in each experi-
FIG 1 -Growth curve for tumour S66.
meiit were essentially the same. More important however was the fact that the
relationship of serum glycoprotein changes to tumour growth was identical in
each experiment. Thegrowth curve ofthetumour (Fig. 1) indicates three phases of
growth. Immediately following implantation, there was a period of slow growth
during which time tumour grafts were becoming established. This wasfollowed by
a period of rapid growth starting between the 10th and 14th day after implanta-
tion and then finally as tumours became large, there was a gradual decrease in
the rate of growth.
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Theserumproteinandglycoprotein changesoccurring duringgrowthofsarcoma
S66 are shown in Table I. Total serum protein (expressed as g./100 ml. serum)
decreased steadily during tumour growth. Electrophoretic analyses of the sera
(Table II) indicated that this loss ofprotein represented a loss ofalbumin together
with /3 and y globulins. The concentration of a, globulin was maintained at the
normal level whilst the levels of °C2 globulins were slightly elevated immediately
following tumour implantation and again at about the time when tumours began
to grow rapidly. Because of the steady loss of total serum protein during tumour
growth, the maintenance ofthe x globulins at or slightly above their normal levels
results in an increase in the relative concentration ofthese proteins in serum.
Increases of serum mucoprotein, expressed either as protein (tyrosine) or
carbohydrate, occurred immediately following tumour implantation and then after
a period oflittle change, there was a further increase to a maximum. This second
increase occurred whilst tumours were still comparatively small (3 to 10 per cent
oftotal bodyweight) and could be correlated with the most active phase oftumour
growth. The later stages of tumour development when tumours were becoming
large (25-31 per cent of total body weight) were associated with decreases in the
concentration of mucoprotein.
The composition of serum mucoprotein, expressed by its carbohydrate/
protein (tyrosine) ratio, was not altered significantly by the large increases of
mucoprotein occurring during the early stages of tumour growth. This suggests
that the increases represent an abnormal production of the normal component.
However, since the mucoprotein fraction isolated by precipitation with phospho-
tungstic acid from perchloric acid filtrates of serum contains a number ofelectro-
phoretically distinct proteins (Mehl, Humphrey and Winzler, 1949), the possibility
remains that abnormal mucoproteins may be present in relatively minor amounts.
Total serum glycoprotein changes closely paralleled those of serum muco-
protein. However these changes mainly represent alterations in the concentration
of the carbohydrate component of mucoprotein and the levels of serum glyco-
protein other than mucoprotein (total serum glycoprotein-mucoprotein carbo-
hydrate) steadily decreased during tumour growth. This was mainly due to the
loss of serum protein and no significant changes were observed in the levels of the
non-mucoprotein glycoprotein fraction when corrected for protein loss
{Total serum glycoprotein - Mucoprotein carbohydrate'
(Total serum Total serum protein
Carcinogen-induced tumour
Theresultsfromthese experiments are shown in TableIII. Total serumprotein
concentration steadily decreased during tumour growth in a manner similar to
that observed with transplanted tumour and the changes of non-mucoprotein
glycoprotein could be accounted forbythis loss ofprotein. In contrast, the concen-
tration of serum mucoprotein was decreased during the early stages of tumour
growth and only attained the normal level when the tumours had reached a
relatively large size.
DISCUSSION
The electrophoretic studies (Table II) indicated that ac1 and °C2 globulins
were maintained at or slightly above their normal levels during growth of trans-
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TABLE III.-Serum Protein and Glycoprotein Changes During Growth of
Methylcholanthrene-induced Tumours in the Rat
(Mean + Standard Deviation)
Carcinogen-treated rats
Days after injection
Normal 65-70 119-150 168-172
Number of animals . . . 12 . 5 5 5
Tumour size (cu. cm.) .. 0-2-5 5 0-11 0 58-138
Totalserumproteing./100ml. 6 29±0410 6-33±0 26 5 91±0 37 5-20±0 20
Total serum glycoprotein (T.CHO) 195±4 192 +6 188±19 163+10
mg./100 ml.
Serum mucoprotein-
(a) Tyrosine(Tyr)mg./100 ml.. 50±2 33±1 33±4 49±6
(b) Carbohydrate (CHO) mg./ 35±1 . 28±1 28±3 35±3
100 ml.
Mucoprotein
. Tyr 0 70±002 . 0 83±0*03 0 88±0 05 0 72±0 02
(Total serum glycoprotein-mucopro- 161± 17 . 164±7 162±9 128±6
tein CHO) mg./100 ml.
Total serum glycoprotein-mucopro- 2-56±0 03 . 2 59±0 12 2 540- 27 2-46±0 09
tein . CHO . Total serumprotein
x 100%
planted tumour (S66) in the rat despite a steady loss of all other serum proteins.
In agreement with recent findings on a globulin changes during growth of trans-
planted tumour in mice (Bernfeld and Homburger, 1955), increases of °C2 globulins
occurred during early stages of tumour development when growth was becoming
most active.
Recently, it has been shown that between 80 and 90 per cent of the serum
mucoprotein component ofnormal and malignant rat serum is distributed between
the ac, and °C2 globulins (Baldwin and Harries, unpublished observations). Thus
at least part of the a globulin changes occurring during tumour growth can be
related to increases of serum mucoprotein. In addition, it has been shown that
total serum glycoprotein changes can be accounted for almost entirely by changes
of serum mucoprotein-carbohydrate. These findings suggest that the major
changes occurring in the serum glycoprotein fractions during tumour growth are
due to alterations ofserum mucoprotein concentration.
The early increase of serum mucoprotein occurring immediately following
tumour implantation almost certainly represents the host's response to the
implantation procedure and the tumour graft. The second increase to a maximum
following a period of little change occurred whilst tumours were still compara-
tively small in size (3 to 10 per cent oftotal body weight) and could be correlated
with the beginning of the most active phase of tumour growth. It is concluded
from these findings that abnormal production of serum mucoprotein can be
relatedtoprocesses occurring during tissue proliferation rather than to the elimina-
tion of tissue glycoproteins following degenerative changes in tumour and sur-
rounding tissue (Catchpole, 1950). This conclusion is further supported by the
finding that mucoprotein levels decreased during the later stagesoftumour growth
when tumours were becoming large.
These findings fully confirm recent observations of Hokkanen, Pyorala and
Taipale (1956) on the mucoprotein changes associated with growth of the I.T.B.
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ascites tumour in the rat and also to a limited extent those of Weimer, Quinn,
Moshin and Nishihara (1957) on the serum glycoprotein changes occurring during
growth ofthe Walker carcinoma. Comparison ofthe findings ofthe latter authors
with those obtained in the present study reveals a number of marked differences.
Thus although serum mucoprotein increases were observed with both tumours at
about the same stage of development, further growth of the Walker carcinoma
was associated with a continued production of mucoprotein whereas in the present
study, decreases towardsthenormalleveloccurredduring thelaterstagesoftumour
growth. In addition, growth of the Walker carcinoma resulted in a marked
decrease in the concentration of serum glycoprotein other than mucoprotein,
which could not be accounted for by loss of serum protein, whilst in the present
study, normal or slightly elevated levels were detected. It is probable that these
variations reflect differences in the growth requirements of the tumours since
Weimer, Quinn, Moshin and Nishihara (1957) showed that even alteration of the
site of implantation of the Walker carcinoma resulted in changes in the serum
glycoprotein pattern.
Serum glycoprotein changes occurring during growth of methylcholanthrene-
induced tumours differed from those observed with transplanted tumour in that
therewasadecrease rather than anincreaseofmucoprotein during theearlystages
of tumour growth. The activity of the induced tumours, expressed in terms of
their growth rate, was very much less than that of the transplanted tumour S66
and so these results are interpreted as indicating that serum mucoproteins are
only elevated during rapid tumour proliferation. The present findings therefore
support the concept that serum mucoprotein increases during tumour growth
occur as a result of proliferative processes and it is also suggested that these
increases are related to the growth activity of the tumour.
SUMMARY
1. Total serum protein concentration steadily decreased during growth of
transplanted tumour, S66 in the rat. This loss of protein represented a loss of all
serum proteins except ac and a2 globulins. Increases in x2 globulin concentration
occurred immediately after tumour implantation and again during the period
ofrapid tumour growth whilst ac globulins were maintained at their normal level.
2. Changes of serum mucoprotein concentration closely paralleled those
observed for x2 globulins: the major increase occurring during the most active
period of tumour growth. Later stages of tumour development were associated
with decreases in concentration ofserum mucoprotein.
3. Total serum glycoprotein changes could be accounted for almost entirely
by the alterations in serum mucoprotein-carbohydrate. The non-mucoprotein
component corrected for loss of serum protein,
Total serum glycoprotein - Mucoprotein CHO\
(Total serum Total serum protein /
showed no significant change during tumour growth.
4. Changes occurring during growth of methylcholanthrene-induced tumours
were different from those observed with transplanted tumour: the major findingSERUM PROTEIN AND GLYCOPROTEIN CHANGES 107
being a decrease rather than an increase of serum mucoprotein. The implications
of these findings are discussed.
Thisworkwassupported by the NottinghamshireCouncil ofthe BritishEmpire
Cancer Campaign.
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